Benzinga··Vandana SinghImmunityBio Secures Japanese BCG Partnership for Bladder Cancer Despite Stock Decline
ImmunityBio secures exclusive U.S. partnership for Tokyo-172 BCG bladder cancer treatment with positive Phase 3 data; patents extended through 2035. Stock falls 1.13%.
IBRXFDA approvalPhase 3 trial